98%
921
2 minutes
20
The 10-item Autism-Spectrum Quotient (AQ10) is frequently used to screen adults for high autistic traits in clinical practice and research. For the past decade, however, the National Institute for Health and Care Excellence has recommended the use of a suboptimal ≥ 7 cutoff value, instead of the optimal ≥ 6 value specified during the AQ10's development. A comprehensive review into the use and reporting of the AQ10 cutoff suggests that this discrepancy has proliferated across the literature, with over 58% of reports citing a suboptimal (27.15%) or ambiguous (31.13%) cutoff value. After examining the use of the AQ10 cutoff in previous research, we drew on 25 published data sets ( = 13,692) to test how applying different AQ10 cutoffs can influence research. Our analyses suggest that a striking 36.80% of the participants classified as having high autistic traits using the ≥ 6 cutoff would be classified as having low autistic traits using the ≥ 7 cutoff. The ≥ 6 cutoff was also found to provide a better balance between the sensitivity and specificity of the AQ10 with respect to a clinical autism diagnosis. Most critically, our analyses showed that even a 1-point difference in the AQ10 cutoff-the error made in the National Institute for Health and Care Excellence guidelines-can meaningfully change both the statistical significance and the magnitude of autism-related effects. These findings demonstrate that the suboptimal use of the AQ10 cutoff can be consequential for research, and we discuss the urgent need to establish and apply appropriate autism screening cutoff values in the future. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1037/pas0001339 | DOI Listing |
Int J Mol Sci
August 2025
Regional Specialist Hospital in Wrocław, Research and Development Centre, 51-124 Wrocław, Poland.
Calprotectin is a calcium-binding protein involved in inflammatory processes. In the context of abdominal aortic aneurysm (AAA), elevated levels of calprotectin may indicate immune system activation and chronic inflammation, which are among the mechanisms contributing to the development and progression of AAA. The receptor for advanced glycation end-products (RAGE) is a receptor that binds various ligands, including advanced glycation end-products formed during the glycation of proteins and lipids under oxidative stress conditions.
View Article and Find Full Text PDFEur J Vasc Endovasc Surg
August 2025
Department of Surgical Sciences, Section of Vascular Surgery, Uppsala University, Uppsala, Sweden. Electronic address:
Objective: The aim of this study was to compare aortic size index (ASI) (aortic diameter/body surface area) with aortic diameter (AD) in patients with infrarenal abdominal aortic aneurysms (AAAs) for screening, diagnosis, and outcomes, focusing on women.
Methods: Cochrane, MEDLINE, and Web of Science Core Collection databases were searched (last update 14 May 2024) for reports on ASI in patients with AAA reporting sex disaggregated data. A systematic review and meta-analysis was performed following the PRISMA guidelines.
Lancet Oncol
September 2025
NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia.
Background: Quantitative parameters derived from gallium-68 [Ga]Ga-prostate-specific membrane antigen (PSMA)-11 PET-CT (PSMA-PET-CT) such as whole-body standardised uptake value (SUV)mean and total tumour volume (PSMA-TTV) have shown prognostic value for response to lutetium-177 [Lu]Lu-PSMA-617 monotherapy in patients with prostate cancer. Adding [Lu]Lu-PSMA-617 to enzalutamide improved overall survival compared with enzalutamide in patients with metastatic castration-resistant prostate cancer in the ENZA-p trial. This prespecified substudy of ENZA-p evaluated baseline PSMA-PET quantitative parameters as predictive and prognostic biomarkers for enzalutamide plus [Lu]Lu-PSMA-617 and enzalutamide monotherapy.
View Article and Find Full Text PDFLancet Oncol
June 2025
Department of Genitourinary Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Background: In the ongoing EV-302 trial, first-line enfortumab vedotin plus pembrolizumab improved progression-free survival and overall survival versus platinum-based chemotherapy in patients with locally advanced or metastatic urothelial cancer. Patient-reported outcomes (PROs) from EV-302 are reported here.
Methods: EV-302 was a phase 3, open-label, two-group, randomised global study to evaluate the combination of enfortumab vedotin plus pembrolizumab versus standard-of-care platinum-based chemotherapy (gemcitabine with cisplatin or carboplatin) in patients with previously untreated locally advanced or metastatic urothelial cancer.
Vascular
May 2025
Division of Vascular and Endovascular Surgery, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
BackgroundThe accumulation of adipose tissue, such as increased epicardial adipose tissue volume (EATV) and visceral fat area (VFA), is associated with the development of cardiovascular (CV) disease. However, little information is available regarding the relationship between EATV and CV death in patients who undergo open surgical repair (OSR) for abdominal aortic aneurysms (AAAs). The aim of this study was to evaluate the association between adipose tissue and CV death and to identify factors related to CV death after AAA repair.
View Article and Find Full Text PDF